Effects of Febuxostat in the Progression of Chronic Kidney Disease in Renal Transplant Recipients

Objective: To see the effect of febuxostat in slowing the progression that treatment with febuxostat improves eGFR in renal transplant recipients having asymptomatic hyperuricemia.Patients and Methods: This randomized controlled trial was carried out in a Department of Nephrology PIMS. A total of 106 post renal transplants recipients having asymptomatic hyperuricemia, were randomly divided into two groups of 53 each by lottery method. One group was given febuxostat for treatment of post renal transplant hyperuricemia while the other one was given a placebo.Results: The mean age of patients was 48.15 years with a male to female ratio 4.6:1. Treatment with febuxostat was linked significantly in lowering the mean uric acid level at 7.01mg/dl, 6.32mg/dl and 5.42mg/dl at 2, 4 and 6 months, respectively, and renal function was better preserved in the patients receiving febuxostat at mean eGFR of 49.74, 48.96 & 48.89 ml/min/1.73m 2 at 2, 4 and 6 months, respectively.Conclusion: In patients with postrenal transplant asymptomatic hyperuricemia, febuxostat showed significant reduction in serum uric acid level with preservation of renal function